All In Biotech

Drug Trial Radar · NCT07661030

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Affiliated People's Hospital of Ningbo University; Wenzhou Central Hospital; Yuyao People's Hospital
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.

Conditions

  • Gout

Interventions

  • DotinuradDrug

    The drug used in the treatment group (from week 1 to 4)and the control group (from week 3 to 4). This is the main intervention factor of the study.

  • colchicineDrug

    The drugs used throughout the treatment and control groups. In this design, it is part of the background treatment or the standard treatment.

  • etoricoxibDrug

    The drugs used by the treatment group and the control group in the first week. It is also part of the background treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the days to resolution from enrolment to the resolution of an acute gout flare between the two groupsTime frame: From enrollment to the end of treatment at 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.